Gan & Lee Insulin Lispro Injection

BIOLOGICAL2 trials

Sponsors

Gan and Lee Pharmaceuticals, USA

Conditions

Diabetes MellitusDiabetes Mellitus, Type 1

Phase 1

PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males

CompletedNCT04235439

Gan and Lee Pharmaceuticals, USADiabetes Mellitus

Start: 2019-04-23End: 2019-07-03Updated: 2020-02-13

Phase 3

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

WithdrawnNCT04254380

Gan and Lee Pharmaceuticals, USADiabetes Mellitus, Type 1

Start: 2019-12-04End: 2020-01-27Updated: 2020-02-05

Related Papers

736-P: Proposed Biosimilar Gan & Lee Insulin Lispro (GL-LIS) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) vs. U.S.- and EU-Licensed Insulin Lispro (LIS)

Diabetes2021-06-01